Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

955
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
955
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

223
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
223

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulsed degenerate optical parametric oscillator based on a nonlinear-fiber Sagnac interferometer.

Optics letters·2007
Same author

Comparison of the incidence and severity of cough induced by sufentanil and fentanyl: a prospective, randomised, double-blind study.

Anaesthesia·2007
Same author

Comparative evaluation of myolaxin and EMLA cream for attenuation of venous cannulation pain: a prospective, randomised, double blind study.

Anaesthesia and intensive care·2007
Same author

HOpe for contrast-induced acute kidney injury.

Kidney international·2007
Same author

Voided urinary cytology in bladder cancer: is it time to review the indications?

Urology·2007
Same author

Early penile rehabilitation following radical prostatectomy: Cleveland clinic experience.

International journal of impotence research·2007
Same journal

Corrigendum to: Sortilin as a Culprit in the Atherosclerosis Plaque Progression: Evidence from Clinical and Experimental Studies.

Current molecular medicine·2026
Same journal

Dynamic Expression of Fibroblast Activation Protein (FAP) During Chronic Pancreatitis (CP) Progression in Mice and Evaluation of FAP-targeted Tracers for Early CP Diagnosis.

Current molecular medicine·2026
Same journal

Causal Relationship Between 91 Inflammatory Factors and Gastritis: A Two-Sample Bidirectional Mendelian Randomization Study.

Current molecular medicine·2026
Same journal

Therapeutic Potential of Pistacia Atlantica Gum in Aspirin-Induced Peptic Ulcers: A Dose-Dependent Approach to Mucosal Protection and Hepatorenal Safety.

Current molecular medicine·2026
Same journal

Identification and Characterization of MicroRNAs Associated with Borax-mediated Anti-tumor Activity through High-throughput Technology.

Current molecular medicine·2026
Same journal

Broad-Spectrum Vaccines: Challenges and Opportunities (A Systematic Review).

Current molecular medicine·2026
See all related articles

Related Experiment Video

Updated: Apr 6, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.4K

Therapies in Development for Non-Infectious Uveitis.

M A Sadiq, A Agarwal, M Hassan

  • 1Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, 985540 Nebraska Medical Center, Omaha, NE 68198-5540, USA. quan.nguyen@unmc.edu.

Current Molecular Medicine
|August 5, 2015
PubMed
Summary
This summary is machine-generated.

New molecular and biologic therapies offer promising treatments for uveitis, aiming for better inflammation control with fewer side effects than traditional corticosteroids. Novel drug delivery systems also enhance treatment efficacy.

More Related Videos

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.3K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.2K

Related Experiment Videos

Last Updated: Apr 6, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.4K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.3K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.2K

Area of Science:

  • Ophthalmology
  • Immunology
  • Pharmacology

Background:

  • Uveitis is an ocular inflammatory condition causing significant vision loss.
  • Current treatments like corticosteroids have limitations and adverse effects.
  • Steroid-sparing agents also present challenges with safety and efficacy.

Purpose of the Study:

  • To review novel molecular agents and biological therapies for uveitis.
  • To highlight emerging strategies for improved uveitis management.
  • To discuss advancements in drug delivery systems for ocular inflammation.

Main Methods:

  • Review of preclinical and clinical studies on novel uveitis treatments.
  • Summarization of data on molecular targets and biological agents.
  • Analysis of new drug delivery systems for intraocular pharmacotherapy.

Main Results:

  • Novel molecular agents and biological therapies show promising efficacy and safety.
  • Monoclonal antibodies demonstrate potential to halt inflammatory processes.
  • Advanced drug delivery systems aim to achieve high intraocular drug levels.

Conclusions:

  • Emerging molecular and biological therapies represent a promising future for uveitis treatment.
  • These novel strategies may offer better inflammation control with reduced adverse effects.
  • New drug delivery systems could enhance therapeutic outcomes in uveitis management.